According to MedCity News, Thermalin Diabetes, a Boston and Cleveland-based company, has raised $5.9 million from private investors in the first tranche of a Series B round.

Thermalin™s world-class team is leveraging breakthroughs with significant IP built on 25 years of research on insulin by Dr. Michael Weiss, Chairman of Biochemistry at Case Western Reserve Medical School (CWRU). Our new molecules, novel formulations, and devices address unmet clinical needs, enable new delivery technologies and reach rapidly developing markets.